Open an account

Biotricity

BTCY · OTC

$0.055+$0.005 (+10.00%)TodayMarket closed ·
Prev close $0.05

About BTCY

Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. The company is headquartered in Redwood City, California and currently employs 46 full-time employees. The company went IPO on 2015-10-26. The firm developed its Bioflux COM technology, comprised of a monitoring device and software components. Its Bioflux and Biocore Pro are integrated electrocardiogram (ECG) device and software solutions for the COM market. The Biocore ECG reporting software allows doctors and labs to view a patient’s ECG data for monitoring and diagnostic purposes. The Bioflux and Biocore Pro platform has a built-in cellular chipset and a real-time embedded operating system which allows its technology to be utilized as an Internet of Things (IoT) platform. The firm has developed several technologies, including Bioheart, Biocare, and Biokit. Biokit is a remote patient monitoring kit that combines a blood pressure cuff, pulse oximeter and a digital thermometer into the Biocare platform to support the collection of additional biometrics for those patients with multiple conditions.

Employees
46
Headquarters
Redwood City, California
Listed
Oct 26, 2015
Sector
Health Care
Industry
Health Care Technology
Website
biotricity.com

BTCY key statistics

Market cap
1.10M
Price-earnings ratio
0.00
Dividend yield
2.18%
Average volume
57.97K
Volume
106.70K
Open price
$0.05
High today
$0.055
Low today
$0.046
52 Week high
$0.6999
52 Week low
$0.0409

Biotricity (BTCY) at a glance

As of Oct 20, 2026, Biotricity (BTCY) shares are priced at $0.055, giving the company a market cap of 1.10M, a price-to-earnings ratio of 0.00 and a dividend yield of 2.18%.

Today the stock has traded between $0.046 and $0.055. The current price is 19.6% above the day's low and 0.0% below its high.

Volume so far is 106.70K shares, above the average of 57.97K shares a day.

Over the past year Biotricity has ranged from $0.0409 to $0.6999, and now sits 2% of the way up that range.

Biotricity met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q4 FY26 it reported -$0.02 per share against an estimate of -$0.0816.

BTCY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 55.8% on average.

  1. Q3 FY24: reported -$0.339 per share against an estimate of -$0.4488
  2. Q4 FY24: reported -$0.469 per share against an estimate of -$0.3672
  3. Q3 FY25: reported -$0.03 per share against an estimate of -$0.0816
  4. Q4 FY25: reported -$0.042 per share against an estimate of -$0.0816
  5. Q1 FY26: reported -$0.03 per share against an estimate of -$0.0918
  6. Q2 FY26: reported -$0.03 per share against an estimate of -$0.0816
  7. Q3 FY26: reported -$0.042 per share against an estimate of -$0.0816
  8. Q4 FY26: reported -$0.02 per share against an estimate of -$0.0816

BTCY news

  • Press releasePRNewswire

    Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users

  • Press releasePRNewswire

    Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform

  • Press releasePRNewswire

    Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand

  • Press releasePRNewswire

    Biotricity Achieves Positive Free Cash Flow Milestone

  • Press releaseACCESSWIRE

    SWK Holdings Provides Portfolio Update

Similar companies

Companies in the same industry as Biotricity

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.